Gedeon Richter PLC (LUX:CHWGR)
Luxembourg · Delayed Price · Currency is EUR · Price in USD | Market Cap | 6.36B +35.3% |
| Revenue (ttm) | 2.42B +8.3% |
| Net Income | 604.82M -2.9% |
| EPS | 3.31 -2.8% |
| Shares Out | n/a |
| PE Ratio | 10.52 |
| Forward PE | 8.36 |
| Dividend | 1.24 (2.94%) |
| Ex-Dividend Date | Jun 3, 2025 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 41.40 |
| Day's Range | n/a |
| 52-Week Range | 27.43 - 43.00 |
| Beta | n/a |
| RSI | 64.02 |
| Earnings Date | Apr 30, 2026 |
About Gedeon Richter
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic ... [Read more]
Financial Performance
In 2025, Gedeon Richter's revenue was 928.96 billion, an increase of 8.33% compared to the previous year's 857.55 billion. Earnings were 232.34 billion, a decrease of -2.89%.
Financial numbers in HUF Financial StatementsNews
Gedeon Richter Plc.: Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care
Gedeon Richter's Side-by-Side Conference on Advancing Women's Health brought together Healthcare practitioners from 40 countries for a dynamic two-day exchange on March 26-27, making it the largest...
Gedeon Richter Plc.: Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon...
Gedeon Richter Earnings Call Transcript: Q3 2025
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
Gedeon Richter Earnings Call Transcript: Q2 2025
First half results show strong revenue and clean EBIT growth, led by women's health and neuropsychiatry, with robust pipeline progress and ESG achievements. Inventory write-offs and FX volatility impacted margins, but full-year guidance remains on track.
Gedeon Richter Earnings Call Transcript: Q1 2025
Q1 2025 saw strong revenue and EBIT growth, driven by pharma sales and FX gains, with robust free cash flow and a solid cash position. Four biosimilar launches are planned within 12 months, and the outlook for general medicines and women's health remains positive.
Gedeon Richter Earnings Call Transcript: Q4 2024
Revenue and profit grew strongly in 2024, with all business units contributing and free cash flow nearly tripling. 2025 guidance targets 10% growth amid lower milestone income and cost control initiatives.
Gedeon Richter Earnings Call Transcript: Q3 2024
Revenue and net profit grew strongly year-over-year, driven by broad-based segment growth and successful M&A. Free cash flow and EBIT improved, with new product launches and biosimilar filings supporting future outlook. FX volatility and regulatory uncertainties remain key risks.
Gedeon Richter Transcript: Investor Update
Recent acquisitions have vertically integrated the business, expanded R&D, and secured control over key assets like E4, positioning the company as a leader in women's health innovation. Ambitions include surpassing €1 billion in sales and achieving over 20% EBIT margin, with new product launches and market expansion driving growth.